Project Grant K23HL171951
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$364K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $102,932 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Johns Hopkins University. The grant, awarded on February 28, 2025, aims to understand key factors associated with bothersome uncertainty and expectation formation in acute respiratory failure (ARF) survivors at hospital discharge, as these factors are potential targets for intervention. The study will characterize the prevalence of...
This $503,496 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to improve treatment and outcomes for patients with hospital-onset sepsis at risk of acute respiratory failure (ARF). The key objectives are to: 1) Identify different clinical presentation phenotypes of hospital-onset sepsis, 2) Develop a predictive model to forecast ARF risk in these patients, and 3) Assess how...
The University of Colorado-Denver received a $126,059 Project Grant from the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports a 5-year research project to investigate the systems biology of acute and chronic multi-organ failure in children with congenital heart disease (CHD).
Specifically, the research will utilize proximity extension assay technology to perform longitudinal measurement of the circulating proteome...
This $480,990 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) Cardiovascular Diseases Research program (CFDA 93.837) supports research on the role of aerocytes, a specialized capillary endothelial cell population, in alveolar epithelial regeneration following acute lung injury. The research aims to investigate how aerocyte-derived signaling, particularly the R-spondin3 molecule, guides the regenerative remodeling of alveolar epithelium and establishes a...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $807,067 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to the University of Virginia to develop novel respiratory kinematic physiomarkers for predicting and preventing severe respiratory failure. The 5-year project aims to pioneer the quantitative documentation of human respiratory kinematic profiles during emergency room visits, identifying features and phenotypes that can improve prediction of respiratory failure...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $641,544 to the University of North Carolina at Chapel Hill (UNC-CH) to develop innovative machine learning methods for analyzing complex biomedical data related to heart, lung, blood, and sleep disorders.
The key objectives of this 4-year project are to: 1) create novel machine learning techniques to uncover causal relationships between...
This Project Grant award, with funding of $394,200.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award will support research to adapt existing interventions for cardiovascular disease (CVD) risk reduction in Black communities into a multicomponent behavioral intervention called "COPDHEART" that is tailored to the needs of Black patients with chronic obstructive pulmonary disease (COPD)....
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research to develop a collaborative care model to deliver a resilience-building intervention for adolescents and young adults (AYAs) with sickle cell disease. The $254,604 award, spanning September 2024 to August 2029, aims to: 1) Determine the feasibility and acceptability of the intervention in a community-based setting; 2)...
This Project Grant award of $191,792 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to adapt and preliminarily test an Individualized Care Plan (ICP) prototype for inpatient vaso-occlusive episode (VOE) care in sickle cell disease (SCD). Awarded to the University of Rochester, the project aims to develop the ICP prototype with a patient-inclusive team and evaluate the feasibility of implementing...
This $196,441 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research to address racial disparities in chronic lung disease (CLD) for preterm infants. The primary goals are to:
Characterize medical and social risk factors associated with respiratory morbidity in preterm infants with CLD, focusing on Black preterm infants
Describe the lived experiences of Black parents of preterm...